Guideline of guidelines: non-muscle-invasive bladder cancer

Solomon L. Woldu, Aditya Bagrodia, Yair Lotan

Research output: Contribution to journalArticlepeer-review

168 Scopus citations


Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.

Original languageEnglish (US)
Pages (from-to)371-380
Number of pages10
JournalBJU international
Issue number3
StatePublished - Mar 1 2017


  • #BladderCancer
  • #blcsm
  • guidelines
  • management
  • non-muscle-invasive bladder cancer

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Guideline of guidelines: non-muscle-invasive bladder cancer'. Together they form a unique fingerprint.

Cite this